Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements & Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Archives
April 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
Categories
Company News
Media
Uncategorized
Videos
10 Nov 2021
VIDEO | AUSBIZ Amplia's $12M plan; what's next for the Aussie medtech
Read More
10 Nov 2021
VIDEO | Proactive Investors, $12.4m Capital Raise
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
26 Oct 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
21 Oct 2021
Switzer Daily | Therapeutics company primed for growth
Read More
07 Oct 2021
MEET THE TEAM | Dr John Lambert, CEO
Read More
04 Oct 2021
VIDEO | Science Advances paper discussed on Proactive
Read More
30 Sep 2021
VIDEO | Amplia featured on Channel 9 News
Read More
30 Sep 2021
BioMelbourne Network | Breakthrough research on pancreatic cancer
Read More
30 Sep 2021
Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models
Read More
30 Sep 2021
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
Read More
30 Sep 2021
Breakthrough research lowers pancreatic cancer’s resistance to chemo
Read More
30 Sep 2021
New FAK research published in Science Advances
Read More
29 Sep 2021
VIDEO | Proactive Lifesciences Webinar
Read More
27 Sep 2021
Proactive Lifesciences Webinar
Read More
22 Sep 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
20 Sep 2021
Proactive | Interview with Dr John Lambert
Read More
26 Jul 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
21 Jul 2021
Amplia Therapeutics returns successful phase one trial results
Read More
1
2
3
4
5